Evaxion Biotech AS has a consensus price target of $8, established from looking at the 6 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Ladenburg Thalmann on March 20, 2024, February 12, 2024, and December 21, 2023. With an average price target of $9.33 between HC Wainwright & Co., HC Wainwright & Co., and Ladenburg Thalmann, there's an implied 200.11% upside for Evaxion Biotech AS from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/20/2024 | EVAX | Buy Now | Evaxion Biotech | $3.11 | 350.16% | HC Wainwright & Co. | Swayampakula Ramakanth | → $14 | Reiterates | Buy → Buy | Get Alert |
02/12/2024 | EVAX | Buy Now | Evaxion Biotech | $3.11 | 350.16% | HC Wainwright & Co. | Swayampakula Ramakanth | → $14 | Initiates | → Buy | Get Alert |
12/21/2023 | EVAX | Buy Now | Evaxion Biotech | $3.11 | — | Ladenburg Thalmann | Ahu Demir | — | Downgrade | Buy → Neutral | Get Alert |
03/31/2023 | EVAX | Buy Now | Evaxion Biotech | $3.11 | 125.08% | Lake Street | Thomas Flaten | $180 → $70 | Maintains | Buy | Get Alert |
11/17/2022 | EVAX | Buy Now | Evaxion Biotech | $3.11 | 253.7% | Oppenheimer | Jeff Jones | $160 → $110 | Maintains | Outperform | Get Alert |
07/18/2022 | EVAX | Buy Now | Evaxion Biotech | $3.11 | 414.47% | Oppenheimer | Jeff Jones | → $160 | Assumes | → Outperform | Get Alert |
The latest price target for Evaxion Biotech (NASDAQ: EVAX) was reported by HC Wainwright & Co. on March 20, 2024. The analyst firm set a price target for $14.00 expecting EVAX to rise to within 12 months (a possible 350.16% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Evaxion Biotech (NASDAQ: EVAX) was provided by HC Wainwright & Co., and Evaxion Biotech reiterated their buy rating.
There is no last upgrade for Evaxion Biotech.
The last downgrade for Evaxion Biotech AS happened on December 21, 2023 when Ladenburg Thalmann changed their price target from N/A to N/A for Evaxion Biotech AS.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evaxion Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evaxion Biotech was filed on March 20, 2024 so you should expect the next rating to be made available sometime around March 20, 2025.
While ratings are subjective and will change, the latest Evaxion Biotech (EVAX) rating was a reiterated with a price target of $0.00 to $14.00. The current price Evaxion Biotech (EVAX) is trading at is $3.11, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.